Last reviewed 2026-04-23 · How we verify

meropenem (active comparator)

Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Complicated intra-abdominal infections, Complicated urinary tract infections, Nosocomial pneumonia.

At a glance

Mechanism of action

This binding results in the disruption of the bacterial cell wall, ultimately leading to cell lysis and death. Meropenem has a broad spectrum of activity against both Gram-positive and Gram-negative bacteria.

Approved indications

• Complicated intra-abdominal infections
• Complicated urinary tract infections
• Nosocomial pneumonia

Common side effects

• Diarrhea
• Nausea
• Vomiting
• Headache
• Injection site reaction

Key clinical trials

• A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
• SYN-004 Safety and Tolerability in Allo-HCT Subjects (PHASE1, PHASE2)
• Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
• A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
• A Platform Trial for Gram Negative Bloodstream Infections (NA)
• Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins (PHASE3)
• To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency (PHASE1)
• Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.